AAPL 250.9362 1.1636% MSFT 439.85 0.5624% NVDA 132.26 2.5987% GOOGL 190.36 1.0403% GOOG 191.585 0.7547% AMZN 224.7026 1.8967% META 605.1 1.3245% AVGO 221.57 -0.9167% TSLA 434.8 -1.211% TSM 195.3 -0.133% LLY 758.87 -0.7637% V 315.9 1.9756% JPM 234.325 1.7168% UNH 493.79 -1.1867% NVO 103.7 -2.1329% WMT 93.89 0.3634% LVMUY 130.52 0.7721% XOM 105.67 -0.7048% LVMHF 649.5 0.6649% MA 526.755 1.3068%
Last update at 2024-12-19T18:51:00Z
United Therapeutics Corp (UTHR) Q2 2024 Earnings Call Highlights: Record Revenue Growth and ...
Wed 09 Oct 24, 07:31 PMCan United Therapeutics Corporation (UTHR) Capitalize on Record Revenue to Drive Future Growth?
Wed 09 Oct 24, 11:56 AMUnited Therapeutics (UTHR) Is Thriving on Strong Demand and Smart Pricing
Sat 21 Sep 24, 01:22 PMStrength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength?
Mon 16 Sep 24, 08:12 AMUnited Therapeutics Shares Thrive
Fri 30 Aug 24, 04:02 PMUnited Therapeutics (UTHR) Up 9.9% Since Last Earnings Report: Can It Continue?
Fri 30 Aug 24, 03:31 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 950.60M | 593.90M | 638.90M | -165.00000M | 758.90M |
| Minority interest | - | - | - | - | - |
| Net income | 727.30M | 475.80M | 514.80M | -104.50000M | 589.20M |
| Selling general administrative | 416.20M | 402.60M | 369.00M | 275.50M | 206.70M |
| Selling and marketing expenses | 70.80M | 64.40M | 54.90M | 60.70M | 59.10M |
| Gross profit | 1789.60M | 1563.00M | 1375.20M | 1331.20M | 1429.10M |
| Reconciled depreciation | 51.30M | 49.90M | 49.90M | 45.90M | 35.90M |
| Ebit | 979.70M | 555.90M | 593.60M | -187.60000M | 790.40M |
| Ebitda | 984.70M | 614.80M | 671.50M | -120.80000M | 826.30M |
| Depreciation and amortization | 5.00M | 58.90M | 77.90M | 66.80M | 35.90M |
| Non operating income net other | 3.30M | 56.60M | 68.80M | 66.80M | -32.60000M |
| Operating income | 979.70M | 555.90M | 593.60M | -187.60000M | 805.40M |
| Other operating expenses | 956.60M | 1129.60M | 889.70M | 1636.40M | 822.40M |
| Interest expense | 32.40M | 18.60M | 23.50M | 44.20M | 13.90M |
| Tax provision | 223.30M | 118.10M | 124.10M | -60.50000M | 169.70M |
| Interest income | 45.20M | 16.70M | 28.60M | 44.20M | 28.60M |
| Net interest income | 12.80M | -1.90000M | 5.10M | 0.00000M | 14.70M |
| Extraordinary items | - | - | - | - | 1.80M |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 223.30M | 118.10M | 124.10M | -60.50000M | 169.70M |
| Total revenue | 1936.30M | 1685.50M | 1483.30M | 1448.80M | 1627.80M |
| Total operating expenses | 809.90M | 1007.10M | 781.60M | 1518.80M | 623.70M |
| Cost of revenue | 146.70M | 122.50M | 108.10M | 117.60M | 198.70M |
| Total other income expense net | -29.10000M | 38.00M | 45.30M | 22.60M | -61.20000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 727.30M | 475.80M | 514.80M | -104.50000M | 589.20M |
| Net income applicable to common shares | 727.30M | 475.80M | 514.80M | -104.50000M | 589.20M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 7167.00M | 6044.50M | 5169.10M | 4615.00M | 3913.40M |
| Intangible assets | 80.50M | 16.50M | 16.60M | 130.10M | 130.30M |
| Earning assets | - | - | - | - | - |
| Other current assets | 166.20M | 219.20M | 100.40M | 88.30M | 133.80M |
| Total liab | 1182.20M | 1247.80M | 1210.20M | 1219.80M | 1133.00M |
| Total stockholder equity | 5984.80M | 4796.70M | 3958.90M | 3395.20M | 2780.40M |
| Deferred long term liab | - | 10.50M | 6.90M | 9.30M | 9.30M |
| Other current liab | 71.00M | 339.10M | 301.60M | 319.20M | 39.60M |
| Common stock | 0.70M | 0.70M | 0.70M | 0.70M | 0.70M |
| Capital stock | 0.70M | 0.70M | 0.70M | 0.70M | 0.70M |
| Retained earnings | 6027.10M | 5042.30M | 4315.00M | 3839.20M | 3325.20M |
| Other liab | - | 76.80M | 104.80M | 79.40M | 67.00M |
| Good will | 33.70M | 28.00M | 28.00M | 28.00M | 28.00M |
| Other assets | - | 413.50M | 370.10M | 1559.00M | 293.80M |
| Cash | 1207.70M | 961.20M | 894.80M | 738.70M | 738.40M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 804.40M | 343.20M | 305.40M | 323.30M | 463.00M |
| Current deferred revenue | 327.80M | - | - | - | 163.50M |
| Net debt | -507.70000M | -161.20000M | -94.80000M | 61.30M | 111.60M |
| Short term debt | 400.00M | - | - | - | 250.00M |
| Short long term debt | 400.00M | - | - | - | 250.00M |
| Short long term debt total | 700.00M | 800.00M | 800.00M | 800.00M | 850.00M |
| Other stockholder equity | -30.20000M | -190.80000M | -333.80000M | -430.50000M | -531.30000M |
| Property plant equipment | - | 861.50M | 780.90M | 731.60M | 738.50M |
| Total current assets | 3551.00M | 3380.30M | 2323.60M | 2167.20M | 1864.50M |
| Long term investments | 1909.80M | 1316.20M | 1649.90M | 1149.60M | 767.50M |
| Net tangible assets | - | 4752.20M | 3914.30M | 3237.10M | 2622.10M |
| Short term investments | 1786.40M | 1877.50M | 1035.90M | 1096.30M | 747.50M |
| Net receivables | 278.90M | 220.40M | 198.70M | 157.40M | 151.40M |
| Long term debt | 300.00M | 800.00M | 800.00M | 800.00M | 600.00M |
| Inventory | 111.80M | 102.00M | 93.80M | 86.50M | 93.40M |
| Accounts payable | 5.60M | 4.10M | 3.80M | 4.10M | 9.90M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -12.80000M | -55.50000M | -23.00000M | -14.20000M | -14.20000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.70M | 0.70M | 0.70M | 0.70M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 5042.30M | 4315.00M | 3839.20M | 3325.20M |
| Treasury stock | - | - | - | - | -2579.20000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 151.80M | 114.30M | 108.20M | 169.90M | 154.60M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 3616.00M | 2664.20M | 2845.50M | 2447.80M | 2048.90M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | 800.00M | 800.00M | 800.00M | 600.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -683.60000M | -366.10000M | -681.60000M | -239.20000M | -466.10000M |
| Change to liabilities | 44.50M | -12.50000M | 38.60M | -16.30000M | -11.00000M |
| Total cashflows from investing activities | -811.50000M | -486.90000M | -738.50000M | -335.40000M | -820.60000M |
| Net borrowings | -7.50000M | - | -51.70000M | 599.30M | -13.20000M |
| Total cash from financing activities | 75.40M | 44.80M | -16.90000M | 611.20M | 6.30M |
| Change to operating activities | -150.60000M | -112.90000M | 16.80M | -201.90000M | 4.70M |
| Net income | 727.30M | 475.80M | 514.80M | -104.50000M | 589.20M |
| Change in cash | 66.40M | 156.10M | 0.30M | 69.20M | -35.90000M |
| Begin period cash flow | 894.80M | 738.70M | 738.40M | 669.20M | 705.10M |
| End period cash flow | 961.20M | 894.80M | 738.70M | 738.40M | 669.20M |
| Total cash from operating activities | 802.50M | 598.20M | 755.70M | -206.60000M | 778.40M |
| Issuance of capital stock | - | - | - | - | 3.90M |
| Depreciation | 51.30M | 49.90M | 49.90M | 45.90M | 35.90M |
| Other cashflows from investing activities | 10.90M | - | 2.40M | -12.50000M | -170.10000M |
| Dividends paid | - | - | -4.70000M | -4.10000M | - |
| Change to inventory | -13.40000M | -7.50000M | 10.30M | 12.90M | 9.30M |
| Change to account receivables | -21.70000M | -41.30000M | -6.00000M | 24.40M | 121.40M |
| Sale purchase of stock | -11.40000M | -10.80000M | -3.70000M | -2.10000M | 19.50M |
| Other cashflows from financing activities | 798.40M | 50.00M | 36.80M | 813.30M | 252.40M |
| Change to netincome | 169.60M | 246.70M | 122.20M | 32.90M | -24.60000M |
| Capital expenditures | 138.80M | 120.80M | 59.30M | 83.70M | 184.40M |
| Change receivables | -21.70000M | -41.30000M | -6.00000M | 24.40M | 121.40M |
| Cash flows other operating | 572.20M | 272.60M | 540.70M | -201.90000M | 58.20M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | 66.40M | 156.10M | 0.30M | 69.20M | -35.90000M |
| Change in working capital | -141.20000M | -174.20000M | 59.70M | -180.90000M | 124.40M |
| Stock based compensation | 106.80M | 138.50M | 163.80M | 45.40M | -26.40000M |
| Other non cash items | 58.30M | 65.90M | -47.00000M | -29.70000M | 1.80M |
| Free cash flow | 663.70M | 477.40M | 696.40M | -290.30000M | 594.00M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics Corporation |
5.00 1.40% | 362.55 | 12.74 | 10.17 | 4.70 | 1.83 | 3.72 | 6.24 |
| NVO Novo Nordisk A/S |
-2.26 2.13% | 103.70 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-1.68 1.57% | 105.12 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-55.6951 12.45% | 391.80 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-4.445 0.62% | 710.17 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
1000 Spring Street, Silver Spring, MD, United States, 20910
| Name | Title | Year Born |
|---|---|---|
| Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. | Founder, Chairman & CEO | 1955 |
| Mr. Michael I. Benkowitz | Pres & COO | 1972 |
| Mr. James C. Edgemond | CFO & Treasurer | 1968 |
| Mr. Paul A. Mahon J.D. | Exec. VP, Gen. Counsel & Corp. Sec. | 1964 |
| Mr. Dewey Steadman C.F.A. | Head of Investor Relations | NA |
| Ms. Holly Hobson | Associate VP of HR | NA |
| Kevin T. Gray | Sr. VP of Strategic Operations & Logistics | NA |
| Mr. Patrick Poisson | Exec. VP of Technical Operations | 1968 |
| Mr. Gil Golden | Sr. VP & Chief Medical Officer | NA |
| Dr. Leigh Peterson | VP of Product Devel. | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...